Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study-Reference-Cited by-同舟云学术

Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study

Published:2024-09 Issue: Volume:265 Page:39-47
ISSN:0002-9394
Container-title:American Journal of Ophthalmology
language:en
Short-container-title:American Journal of Ophthalmology

Author:

Wai Karen M.^ORCID,Mishra Kapil,Koo Euna^ORCID,Ludwig Cassie Ann^ORCID,Parikh Ravi^ORCID,Mruthyunjaya Prithvi,Rahimy Ehsan

Funder

National Eye Institute

Publisher

Elsevier BV

Reference30 articles.

1. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021;Ong;Lancet,2023

2. How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology;May;Ther Adv Endocrinol Metab,2019

3. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications;Zheng;Nat Rev Endocrinol,2018

4. New anti-hyperglycaemic agents for type 2 diabetes and their effects on diabetic retinopathy;Saw;Eye,2019

5. Role of Glucagon-Like Peptide-1 (GLP-1) receptor agonists in cardiovascular risk management in patients with type 2 diabetes mellitus: a systematic review;Parab;Cureus,2023

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial of the Special Issue “Molecular Research and Recent Advances in Diabetic Retinopathy”;Biomedicines;2024-08-16

2. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide;JAMA Ophthalmology;2024-08-01